Induction therapy with adalimumab leads to rapid improvement in the health-related quality of life of patients with moderate to severe Crohn's disease Maintenance therapy with adalimumab results ...

Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira biosimilar approved by the FDA and the fourth to receive interchangeability status.

Slower tapering of adalimumab reduced the recurrence risk for noninfectious uveitis by 60% in pediatric patients compared with faster tapering, and starting the tapering after at least 2 years of ...

Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort ...

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.